Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20672666 | 1.00 | PKM (0.61) | PKMMEN1KMT2AMAPTGRIN1 | |
| SCHEMBL14696598 | 0.83 | MEN1 (0.59) | PKMMEN1KMT2AMAPTGRIN1 | |
| SCHEMBL31090423 | 0.82 | PKM (0.44) | PKMMEN1KMT2AMAPTLMNA | |
| SCHEMBL20672608 | 0.82 | MEN1 (0.44) | PKMMEN1KMT2AMAPTGRIN1 | |
| SCHEMBL1003347 | 0.81 | MEN1 (0.58) | PKMMEN1KMT2AMAPTGRIN1 | |
| SCHEMBL7453250 | 0.81 | MEN1 (0.58) | PKMMEN1KMT2AMAPTGRIN1 | |
| SCHEMBL20604787 | 0.81 | MEN1 (0.58) | PKMMEN1KMT2AMAPTGRIN1 | |
| SCHEMBL29223865 | 0.81 | MEN1 (0.58) | PKMMEN1KMT2AMAPTGRIN1 | |
| SCHEMBL24138929 | 0.81 | GRIN2D (0.49) | PKMMEN1KMT2AMAPTGRIN1 | |
| SCHEMBL12858577 | 0.80 | P2RX7 (0.53) | PKMMEN1KMT2AMAPTGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501438-B2 | Pyridoimidazole derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-03-10 | — | — | US | claimed |
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | US | claimed |
| CN-119707829-A | 2-Phenyl-benzo nitrogen-containing heterocyclic compound, and preparation method and application thereof | 合肥大学 | 2025-03-28 | — | — | CN | disclosed |
| US-20240132492-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | JINAN UNIVERSITY (CN) | 2024-04-25 | — | — | US | disclosed |
| CN-115348963-B | Pyridopyrimidine compound and application thereof | 暨南大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-111432810-B | Aminoadamantane nitrate compounds and their use for treating CNS disorders | 潘诺拉马研究公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4310084-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | Jinan University (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-20230130425-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230130425-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. | 2023-04-27 | — | — | US | disclosed |
| CN-115348963-A | Pyridopyrimidine compound and application thereof | 暨南大学 | 2022-11-15 | — | — | CN | disclosed |
| WO-2022188755-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | 暨南大学 | 2022-09-15 | — | — | WO | disclosed |
| WO-2019104020-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019104020-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | PANORAMA RESEARCH, INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| US-20180215699-A1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2018-08-02 | — | — | US | disclosed |
| EP-3328826-A1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017017116-A1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-02 | — | — | WO | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-7501438-B2 | Pyridoimidazole derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-03-10 | — | — | US | disclosed |
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132492-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | AKT3, AKT1S1, AKT2 | PKM 282/4885MEN1 2238/4885KMT2A 2151/4885 |
| US-20180215699-A1 | NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | PKM 2056/4885MEN1 1052/4885KMT2A 1113/4885 |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | PKM 3506/4885MEN1 2310/4885KMT2A 4781/4885 |
| US-20230130425-A1 | AMINOADAMANTYL NITRATE COMPOUNDS AND THEIR USE TO TREAT CNS DISORDERS | NLN, SLC1A2, AANAT | PKM 1091/4885MEN1 1333/4885KMT2A 1928/4885 |
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | CNR1, CNR2, OPRK1 | PKM 3973/4885MEN1 1588/4885KMT2A 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.